Signore A, Beverley P C, Parman A, Negri M, Pozzilli P
ICRF, HTIG, Faculty of Clinical Sciences, University College London.
Exp Clin Endocrinol. 1987 Aug;89(3):301-6. doi: 10.1055/s-0029-1210654.
Human recombinant interleukin-2 (IL-2) was labelled with Iodine-123 using modified Bolton and Hunter method. Separation from free iodine was performed by gel filtration chromatography using a Sephadex G10 column. HPLC analysis of labelled IL-2 showed that 98% of TCA precipitable radioactivity eluted in a single peak. The immunoreactivity of 123I-labelled IL-2 was determined by divert binding using the Fluorescence Activated Cell Sorter (FACS) and by receptor binding assay of IL-2 to activated lymphocytes. To demonstrate in vivo binding to activated lymphocytes, 123I-labelled IL-2 was injected intravenously into a newly diagnosed diabetic BB/Wistar rat. Higher radioactivity was detected in the pancreas and in the lymph nodes of the BB/W rat compared to a normal rat. These preliminary data show that 123I-labelled IL-2 retains its immunoreactivity and capacity to bind to activated lymphocytes both in vitro and in vivo and may be used for in vivo localization of lymphocytic infiltration in Type 1 diabetes.
采用改良的博尔顿-亨特法用碘-123标记重组人白细胞介素-2（IL-2）。使用葡聚糖凝胶G10柱通过凝胶过滤色谱法分离游离碘。对标记的IL-2进行高效液相色谱分析表明，98%的三氯乙酸可沉淀放射性在单个峰中洗脱。通过使用荧光激活细胞分选仪（FACS）的分流结合以及IL-2与活化淋巴细胞的受体结合试验来测定123I标记的IL-2的免疫反应性。为了证明在体内与活化淋巴细胞的结合，将123I标记的IL-2静脉注射到新诊断的糖尿病BB/Wistar大鼠体内。与正常大鼠相比，在BB/W大鼠的胰腺和淋巴结中检测到更高的放射性。这些初步数据表明，123I标记的IL-2在体外和体内均保留其免疫反应性以及与活化淋巴细胞结合的能力，可用于1型糖尿病中淋巴细胞浸润的体内定位。
